RESUMO
Sodium metal batteries have garnered significant attention due to their high theoretical specific capacity, cost effectiveness, and abundant availability. However, the propensity for dendritic sodium formation, stemming from the highly reactive nature of the sodium metal surface, poses safety concerns, and the uncontrollable formation of the solid-electrolyte interphase (SEI) leads to large cell impedance and battery failures. In this study, we present a novel approach where we have successfully developed a stable fluorinated artificial SEI layer on the sodium metal surface by employing various weight percentages of tin fluoride in a dimethyl carbonate solution, utilizing a convenient, cost-effective, and single-step method. The resulting fluoride-rich protective layer effectively stabilized the Na metal surfaces and significantly enhanced cycling stability. The engineered artificial SEI layer demonstrated an enhanced lifetime of Na metal symmetric cells of over 3.5 times, over 700 h at the current density of 0.25 mA/cm2, in cycling performance compared to the untreated sodium, which is attributed to the suppression of dendrite formation and the reduction of undesired SEI formation during high-current cycling.
RESUMO
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) mutations may diminish vaccine-induced protective immune responses, particularly as antibody titers wane over time. Here, we assess the effect of SARS-CoV-2 variants B.1.1.7 (Alpha), B.1.351 (Beta), P.1 (Gamma), B.1.429 (Epsilon), B.1.526 (Iota), and B.1.617.2 (Delta) on binding, neutralizing, and angiotensin-converting enzyme 2 (ACE2)competing antibodies elicited by the messenger RNA (mRNA) vaccine mRNA-1273 over 7 months. Cross-reactive neutralizing responses were rare after a single dose. At the peak of response to the second vaccine dose, all individuals had responses to all variants. Binding and functional antibodies against variants persisted in most subjects, albeit at low levels, for 6 months after the primary series of the mRNA-1273 vaccine. Across all assays, B.1.351 had the lowest antibody recognition. These data complement ongoing studies to inform the potential need for additional boost vaccinations.
